Nifty
Sensex
:
:
11914.40
40359.41
-54.00 (-0.45%)
-215.76 (-0.53%)

Pharmaceuticals & Drugs

Rating :
46/99  (View)

BSE: 540222 | NSE: LAURUSLABS

335.15
2.20 (0.66%)
22-Nov-2019 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  328.05
  •  344.00
  •  328.00
  •  332.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  85251
  •  285.72
  •  418.80
  •  303.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,551.17
  • 26.77
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,584.07
  • 0.45%
  • 2.20

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.73%
  • 5.36%
  • 14.39%
  • FII
  • DII
  • Others
  • 0.08%
  • 30.58%
  • 16.86%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.56
  • 6.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.78
  • -2.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.60
  • -21.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 33.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.45

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 14.11

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
712.42
588.28
21.10%
550.57
539.02
2.14%
635.16
560.24
13.37%
529.46
478.93
10.55%
Expenses
574.62
512.56
12.11%
467.31
458.46
1.93%
523.17
443.36
18.00%
441.74
391.58
12.81%
EBITDA
137.81
75.73
81.98%
83.26
80.55
3.36%
111.99
116.88
-4.18%
87.71
87.35
0.41%
EBIDTM
19.34%
12.87%
15.12%
14.94%
17.63%
20.86%
16.57%
18.24%
Other Income
1.36
10.53
-87.08%
4.50
2.59
73.75%
1.62
5.08
-68.11%
1.42
9.94
-85.71%
Interest
25.57
24.64
3.77%
22.53
22.32
0.94%
17.57
23.26
-24.46%
23.65
17.76
33.16%
Depreciation
47.83
39.82
20.12%
45.84
38.19
20.03%
43.47
34.61
25.60%
42.71
30.98
37.86%
PBT
65.77
21.79
201.84%
19.39
22.62
-14.28%
52.57
64.09
-17.97%
22.77
48.55
-53.10%
Tax
9.22
5.58
65.23%
4.29
6.07
-29.32%
9.39
19.01
-50.60%
4.95
13.68
-63.82%
PAT
56.55
16.21
248.86%
15.09
16.56
-8.88%
43.18
45.08
-4.21%
17.82
34.87
-48.90%
PATM
7.94%
2.76%
2.74%
3.07%
6.80%
8.05%
3.37%
7.28%
EPS
5.29
1.52
248.03%
1.42
1.56
-8.97%
4.06
4.25
-4.47%
1.67
3.28
-49.09%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
2,427.61
2,291.92
2,056.17
1,904.65
1,777.58
1,326.59
1,159.72
Net Sales Growth
12.05%
11.47%
7.96%
7.15%
34.00%
14.39%
 
Cost Of Goods Sold
1,260.40
1,224.80
1,056.02
989.29
1,000.15
821.27
720.43
Gross Profit
1,167.21
1,067.12
1,000.15
915.36
777.43
505.32
439.29
GP Margin
48.08%
46.56%
48.64%
48.06%
43.74%
38.09%
37.88%
Total Expenditure
2,006.84
1,935.93
1,642.85
1,497.01
1,415.38
1,131.46
956.09
Power & Fuel Cost
-
109.37
94.21
66.27
57.95
49.86
35.03
% Of Sales
-
4.77%
4.58%
3.48%
3.26%
3.76%
3.02%
Employee Cost
-
276.33
238.14
204.73
175.46
131.38
103.25
% Of Sales
-
12.06%
11.58%
10.75%
9.87%
9.90%
8.90%
Manufacturing Exp.
-
178.96
150.78
139.47
106.97
80.61
47.96
% Of Sales
-
7.81%
7.33%
7.32%
6.02%
6.08%
4.14%
General & Admin Exp.
-
97.48
73.17
65.42
49.09
28.39
27.30
% Of Sales
-
4.25%
3.56%
3.43%
2.76%
2.14%
2.35%
Selling & Distn. Exp.
-
31.96
24.09
22.65
16.49
12.46
12.54
% Of Sales
-
1.39%
1.17%
1.19%
0.93%
0.94%
1.08%
Miscellaneous Exp.
-
17.03
6.44
9.18
9.27
7.49
9.58
% Of Sales
-
0.74%
0.31%
0.48%
0.52%
0.56%
0.83%
EBITDA
420.77
355.99
413.32
407.64
362.20
195.13
203.63
EBITDA Margin
17.33%
15.53%
20.10%
21.40%
20.38%
14.71%
17.56%
Other Income
8.90
16.15
29.19
33.44
4.36
34.07
8.82
Interest
89.32
88.19
79.64
99.90
111.11
101.11
58.71
Depreciation
179.85
164.19
125.45
105.98
86.41
61.53
32.88
PBT
160.50
119.75
237.42
235.19
169.04
66.57
120.86
Tax
27.85
25.99
69.81
43.86
34.90
-1.55
23.64
Tax Rate
17.35%
21.70%
29.40%
18.65%
20.65%
-2.33%
19.56%
PAT
132.64
93.76
167.61
191.33
134.14
68.12
97.22
PAT before Minority Interest
132.64
93.76
167.61
191.33
134.14
68.12
97.22
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
5.46%
4.09%
8.15%
10.05%
7.55%
5.13%
8.38%
PAT Growth
17.67%
-44.06%
-12.40%
42.63%
96.92%
-29.93%
 
Unadjusted EPS
12.44
8.83
15.83
20.78
21.37
44.27
63.56

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,558.41
1,482.64
1,330.45
856.80
722.10
358.42
Share Capital
106.44
106.03
105.76
82.38
82.13
77.84
Total Reserves
1,446.60
1,370.75
1,218.84
771.47
637.03
277.22
Non-Current Liabilities
295.49
174.30
132.34
428.11
363.73
203.92
Secured Loans
258.71
141.66
124.56
353.61
303.68
188.17
Unsecured Loans
0.00
0.00
0.00
106.13
0.00
0.00
Long Term Provisions
30.05
20.84
14.59
6.77
5.13
3.93
Current Liabilities
1,423.90
1,306.89
1,120.75
883.75
802.49
710.87
Trade Payables
488.31
312.33
263.10
247.61
230.81
227.47
Other Current Liabilities
244.50
231.26
199.11
141.05
133.34
164.25
Short Term Borrowings
684.21
758.52
644.17
481.42
431.63
312.18
Short Term Provisions
6.89
4.78
14.37
13.66
6.70
6.97
Total Liabilities
3,277.80
2,963.83
2,583.54
2,168.66
1,888.32
1,273.21
Net Block
1,629.07
1,480.80
1,229.93
1,021.03
801.01
499.27
Gross Block
2,105.42
1,793.75
1,418.58
1,106.33
986.17
623.32
Accumulated Depreciation
476.35
312.95
188.65
85.30
185.16
124.04
Non Current Assets
1,814.84
1,716.23
1,443.71
1,165.92
1,024.41
696.70
Capital Work in Progress
109.63
163.18
143.26
69.60
109.67
116.10
Non Current Investment
3.40
3.40
3.40
7.04
7.45
0.00
Long Term Loans & Adv.
25.58
29.36
25.95
29.22
93.94
68.50
Other Non Current Assets
47.16
39.50
41.17
39.03
12.34
12.82
Current Assets
1,462.96
1,247.59
1,139.82
1,002.73
862.27
574.81
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
681.94
584.78
509.05
487.09
475.50
328.10
Sundry Debtors
709.94
570.59
567.61
444.86
285.07
194.88
Cash & Bank
3.02
3.06
4.09
28.77
58.88
23.20
Other Current Assets
68.06
30.53
34.07
18.14
42.82
28.64
Short Term Loans & Adv.
35.22
58.63
25.01
23.86
22.75
19.80
Net Current Assets
39.05
-59.30
19.07
118.98
59.78
-136.06
Total Assets
3,277.80
2,963.82
2,583.53
2,168.65
1,888.32
1,273.21

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
297.66
342.49
331.99
181.97
-64.71
121.23
PBT
119.75
237.42
235.19
169.04
66.57
120.86
Adjustment
255.27
216.47
199.38
200.57
136.26
83.06
Changes in Working Capital
-52.04
-49.48
-52.45
-154.37
-250.72
-59.27
Cash after chg. in Working capital
322.99
404.41
382.12
215.23
-47.89
144.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-25.32
-61.91
-50.13
-33.26
-16.82
-23.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-252.88
-384.15
-288.67
-312.20
-396.95
-311.82
Net Fixed Assets
-254.84
-394.43
-354.15
-76.75
-353.86
Net Investments
-6.57
-1.22
-24.40
-7.01
-18.65
Others
8.53
11.50
89.88
-228.44
-24.44
Cash from Financing Activity
-44.77
42.24
-53.61
103.32
486.08
203.03
Net Cash Inflow / Outflow
0.02
0.59
-10.30
-26.91
24.42
12.44
Opening Cash & Equivalents
3.00
2.42
12.81
39.53
15.11
2.67
Closing Cash & Equivalent
2.97
3.00
2.42
12.81
39.53
15.11

Financial Ratios

Standalone /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
145.91
139.28
125.25
499.30
419.61
189.14
ROA
3.00%
6.04%
8.05%
6.61%
4.31%
7.64%
ROE
6.19%
11.97%
18.12%
18.65%
14.47%
33.42%
ROCE
8.22%
13.68%
16.52%
16.35%
13.74%
19.96%
Fixed Asset Turnover
1.18
1.29
1.53
1.73
1.66
1.87
Receivable days
101.97
100.40
95.66
73.56
65.47
61.02
Inventory Days
100.87
96.48
94.12
97.00
109.61
102.73
Payable days
72.80
61.13
59.14
58.52
69.29
86.77
Cash Conversion Cycle
130.03
135.75
130.64
112.05
105.79
76.98
Total Debt/Equity
0.67
0.66
0.64
1.20
1.14
1.54
Interest Cover
2.36
3.98
3.35
2.52
1.66
3.06

News Update


  • USFDA completes inspection at Laurus Labs’ Unit 1&3 of Visakhapatnam facility
    22nd Nov 2019, 09:05 AM

    The inspection was carried out from November 18, 2019 to November 21, 2019

    Read More
  • USFDA completes inspection at Laurus Labs’ Visakhapatnam facility
    9th Nov 2019, 09:43 AM

    The inspection was carried out from November 04 - 08, 2019

    Read More
  • Laurus Labs - Quarterly Results
    31st Oct 2019, 17:34 PM

    Read More
  • Laurus Labs agrees to acquire stake in Phekolong Pharmaceuticals
    19th Sep 2019, 09:52 AM

    This transaction will provide the company access to the South African public antiretroviral sector

    Read More
  • Laurus Labs gets EIR from USFDA for API Units 1& 3 at Visakhapatnam
    5th Sep 2019, 11:02 AM

    In FDF segment, the company also received GF ERP approval for FDC TLE 400 for supply in GF funded projects

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.